Regulatory FDA approves MSD’s Keytruda combinations for MIBC Pharmaceutical TechnologyThe FDA has approved two of MSD's anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC.OncologyRead full story pharminent July 13, 2026 (Last updated: July 13, 2026) Pharmaceutical Technology The FDA has approved two of MSD’s anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC. Oncology Read full story Post navigation Previous: Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen FailureNext: “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026